EP Biocomposites PAT rises 41.5% on revenue growth in FY26

1 min read     Updated on 29 May 2026, 11:11 AM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

EP Biocomposites Limited reported a 41.5% increase in net profit to ₹145.83 lakh for FY26, driven by a 13.6% rise in revenue to ₹1,363.98 lakh and improved operational efficiency. EBITDA grew 26.23% to ₹237.83 lakh with margins expanding to 17.44%, while net worth crossed ₹12 crore and ROCE improved to 16%. The company successfully utilized IPO proceeds for capacity expansion and debt repayment, strengthening its balance sheet with total assets rising to ₹1,873.14 lakh.

powered bylight_fuzz_icon
40840981

*this image is generated using AI for illustrative purposes only.

EP Biocomposites Limited reported a 41.5% increase in net profit to ₹145.83 lakh for the financial year ended March 31, 2026, driven by a 13.6% rise in revenue and improved operational efficiency. Revenue from operations grew to ₹1,363.98 lakh from ₹1,200.62 lakh in the previous year. The board of directors approved the audited financial statements for the year at a meeting held on May 26, 2026.

The company’s EBITDA for FY26 stood at ₹237.83 lakh, a 26.23% increase from ₹188.41 lakh in FY25, with margins expanding to 17.44%. Profit before tax improved to ₹193.73 lakh from ₹141.70 lakh in the same period. Earnings per share (EPS) increased to ₹8.67 from ₹6.13 in the previous year. The statutory auditors carried out the audit of the financial statements, confirming compliance with applicable accounting standards.

Financial Performance

The following table outlines the key financial metrics for EP Biocomposites Limited for the year ended March 31, 2026:

Metric FY26 (₹ in Lakhs) FY25 (₹ in Lakhs)
Revenue from Operations 1,363.98 1,200.62
Total Income 1,378.10 1,211.50
Total Expenses 1,184.37 1,069.80
EBITDA 237.83 188.41
Profit Before Tax 193.73 141.70
Net Profit 145.83 103.08
Earnings Per Share (Basic) 8.67 6.13

Operational Highlights

Net worth crossed ₹12 crore as of March 31, 2026, reflecting continued financial strengthening. Return on Investment (ROI) stood at 14%, while Return on Capital Employed (ROCE) improved to 16% during FY26. The company successfully utilized IPO proceeds towards capacity expansion, working capital, and business growth initiatives, strengthening the balance sheet through partial debt repayment and improved liquidity.

Balance Sheet Highlights

The company’s balance sheet strengthened with total assets increasing to ₹1,873.14 lakh as of March 31, 2026, compared to ₹1,662.66 lakh a year ago. Shareholders' funds rose to ₹1,205.30 lakh from ₹1,059.48 lakh, supported by reserves and surplus which grew to ₹1,037.15 lakh. Cash and cash equivalents improved significantly to ₹215.35 lakh from ₹161.67 lakh, indicating robust liquidity.

Historical Stock Returns for EP Biocomposites

1 Day5 Days1 Month6 Months1 Year5 Years
+1.79%+1.79%+25.34%+9.80%-9.26%-37.38%

How does EP Biocomposites plan to sustain the 26.23% EBITDA growth margin in the face of potential raw material price volatility?

What specific new markets or product lines is the company targeting with the recently completed capacity expansion?

Will the company consider declaring dividends in the upcoming fiscal year given the robust cash reserves and improved liquidity?

EP Biocomposites Limited Partners with IISc Bengaluru for Advanced Wastewater Treatment Solutions

1 min read     Updated on 18 Feb 2026, 09:13 AM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

EP Biocomposites Limited has signed a technical consultancy agreement with the Indian Institute of Science (IISc), Bengaluru, to strengthen its capabilities in advanced wastewater treatment solutions. The collaboration focuses on technical consultancy, design review, and expert inputs for non-biological wastewater treatment systems, enabling the company to offer unique non-biological treatment solutions for wastewater recycling. The partnership is expected to enhance process efficiency, system reliability, and regulatory compliance while supporting the company's long-term strategy of providing innovative and environmentally responsible solutions for industrial and municipal applications.

powered bylight_fuzz_icon
32931834

*this image is generated using AI for illustrative purposes only.

EP Biocomposites Limited has announced a strategic technical consultancy agreement with the Indian Institute of Science (IISc), Bengaluru, marking a significant step toward strengthening its capabilities in advanced wastewater treatment solutions. The collaboration aims to enhance the company's technical and research-backed expertise through expert consultancy and design inputs from one of India's premier research institutions.

Partnership Overview

The agreement establishes a framework for technical collaboration focused on advanced wastewater treatment technologies. IISc will provide technical consultancy and expert advisory support for system design and process optimization, enabling EP Biocomposites to leverage cutting-edge research and scientific expertise in developing innovative treatment solutions.

Parameter: Details
Partner: Indian Institute of Science (IISc), Bengaluru
Agreement Type: Technical consultancy and expert advisory services
Scope: Wastewater treatment solutions
Geographic Focus: Domestic
Nature: Non-related party transaction

Technical Scope and Capabilities

The collaboration centers on technical consultancy, design review, and expert inputs relating to non-biological wastewater treatment systems. This partnership is expected to enable EP Biocomposites to offer unique non-biological treatment solutions for wastewater recycling, representing a differentiated approach in the market. The agreement specifically focuses on:

  • System design optimization
  • Process efficiency enhancement
  • Technical advisory support
  • Expert inputs for non-biological treatment systems

Strategic Benefits and Market Impact

The partnership is designed to deliver multiple strategic advantages for EP Biocomposites. The collaboration is expected to enhance process efficiency, system reliability, and compliance with evolving environmental regulations. By leveraging IISc's research expertise, the company aims to differentiate its offerings in the competitive wastewater treatment market.

Expected Benefits: Description
Technical Enhancement: Strengthened research-backed capabilities
Market Differentiation: Unique non-biological treatment solutions
Compliance Support: Enhanced regulatory compliance capabilities
Operational Efficiency: Improved process efficiency and system reliability

Alignment with Corporate Strategy

This technical collaboration aligns with EP Biocomposites' long-term strategy of providing innovative, environmentally responsible, and technology-driven solutions. The partnership supports the company's focus on sustainable water management practices and positions it to expand its presence in both industrial and municipal wastewater treatment applications.

The agreement structure ensures focused technical support while maintaining operational flexibility. IISc's involvement is limited to technical consultancy and advisory services, with construction, equipment supply, or post-installation operations requiring separate agreements if pursued in the future.

Historical Stock Returns for EP Biocomposites

1 Day5 Days1 Month6 Months1 Year5 Years
+1.79%+1.79%+25.34%+9.80%-9.26%-37.38%

More News on EP Biocomposites

1 Year Returns:-9.26%